IMMUNOLOGICAL AND VIROLOGIC OUTCOMES WITHIN TEN YEARS OF COMBINED ANTIRETROVIRAL THERAPY INITIATED BEFORE ONE YEAR OF

Francis Ateba Ndongo1, Mathurin Cyrille Tejiokem2, Calixte Ida Penda3

  • 1MD,PhD, University of Garoua; Centre Mère et Enfant de la Fondation Chantal Biya; Ministry of Public Health; Yaounde, Cameroon;

Insights

Early combined Antiretroviral Therapy (cART) in children with perinatal HIV shows long-term benefits but is hampered by initial high mortality. Early infant HIV screening is crucial to improve outcomes and prevent advanced disease.

Area of Science:

  • Pediatric Infectious Diseases
  • HIV/AIDS Research
  • Public Health in Sub-Saharan Africa

Background:

  • Perinatal HIV infection presents significant long-term health challenges for children.
  • Early initiation of combined Antiretroviral Therapy (cART) is critical for managing pediatric HIV.
  • Understanding long-term outcomes of early cART in resource-limited settings is essential.

Purpose of the Study:

  • To evaluate immunological and virologic outcomes within 10 years of early cART initiation in Cameroonian children with perinatal HIV.
  • To identify factors associated with long-term treatment success in this population.
  • To inform public health strategies for pediatric HIV management.

Main Methods:

  • Prospective cohort study conducted in 3 referral hospitals in Cameroon.
  • Time-to-event analysis used to assess probabilities of viral suppression, sustained viral suppression, immunocompetence, and mortality.
  • Data collected on demographics, treatment regimens, and home conditions.

Main Results:

  • At 10 years, an estimated 22.0% mortality occurred, primarily in the first two years due to advanced HIV disease.
  • Viral suppression (VS) was achieved by 72.0% of children, with 70.0% maintaining it.
  • Immunocompetence increased significantly from 45.3% at baseline to 88.6% at 10 years.
  • Receiving ritonavir-boosted lopinavir (LPV/r)-based regimens and baseline immunocompetence were associated with sustained VS.

Conclusions:

  • High early mortality significantly impairs the long-term efficacy of early cART in children with perinatal HIV.
  • Community-based screening strategies are vital for early HIV detection in infants before advanced disease develops.
  • Optimizing treatment regimens and early intervention are key to improving long-term survival and health in vertically infected children.
Abstract

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.4K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
827
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
235